About 100 reports

  • Causes of gastroparesis

These muscles contract to break up the food and lead to its movement through the gastrointestinal tract.

  • Diabetes
  • Forecast
  • Cadila Healthcare Ltd
  • GlaxoSmithKline plc
  • Valeant Pharmaceuticals International, Inc.
  • Vendor landscape
  • ASTRAZENECA

These agents are associated with reduced rates of hypoglycemia, moderate and continuous weight loss, and gastrointestinal side effects such as nausea and vomiting.

  • Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • ASTRAZENECA
  • MERCK

Its products target the gastrointestinal, metabolic, genitourinary, musculoskeletal, inflammation, ophthalmic, neurology, and pulmonary therapeutic areas.

  • Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

BRAIN STROKE The blood flow disturbance in the gastrointestinal tract can lead to serious illness such as arterial or venous occlusion or hypotonia, peptic ulcer, and gastrointestinal tract ischemia, which may lead to extensive necrosis of the intestine.

  • Diabetes
  • World
  • GE Healthcare Limited
  • Koninklijke Philips N.V.
  • Medtronic, Inc.
  • Pipeline analysis

Sotagliflozin is a small molecule and exhibits its mechanism by inhibiting SGLT-##, which helps absorb glucose and galactose in the gastrointestinal (GI) tract, and SGLT-##, which helps in glucose reabsorption by the kidney.

  • Diabetes
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Nu clear receptor, 1, 3%
  • DIABETES AND OBESITY THERAPEUTICS MARKET, GLOBAL, REVENUE FORECAST FOR ERTUGLIFLOZIN

As previously outlined, Xenical is a gastrointestinal lipase inhibitor that acts specifically in the lumen of the stomach and small intestine.

  • Diabetes
  • World
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • the illness. Consequently, patients in this region are highly engaged and well informed about...

Diseases covered under such programs include most cardiovascular & gastrointestinal disorders, asthma, breast cancer, chronic-obstructive pulmonary disease, coronary heart disease & heart failure, diabetes etc.

  • Diabetes
  • World
  • Market Size
  • Animas Corporation
  • Insulet Corporation
  • REGULATION OF GLUCOSE METABOLISM

The post-meal rise in blood glucose and the presence of certain gastrointestinal hormones stimulate the production of insulin.

  • Diabetes
  • DexCom, Inc.
  • LifeScan, Inc.
  • Medtronic, Inc.
  • Roche Group

GENEREX BIOTECHNOLOGY Advantage of Oral-Lyn Improving compliance: The alternatives to injectable insulin include insulin patches, insulin pumps, inhaled insulin, oral formulations designed to restrict insulin digestion in the gastrointestinal tract, and oral formulations for buccal delivery

  • Diabetes
  • Europe
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Oramed Pharmaceuticals Inc.
  • 7.1 OVERVIEW

DESPITE ITS LOW COST, GASTROINTESTINAL (GI) SIDE EFFECTS ARE VERY COMMON WITH ACARBOSE, WHICH HAS PREVENTED ITS WIDESPREAD USE.

  • Diabetes
  • Europe
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

However, the need for frequent dosing and the drug' s gastrointestinal side effects are a challenge in terms of patient adherence.

  • Diabetes
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Novo Nordisk Group
  • VIVUS, Inc.
  • MARKET ANALYSIS 2016

Improving compliance: The alternatives to injectable insulin include insulin patches, insulin pumps, inhaled insulin, oral formulations designed to restrict insulin digestion in the gastrointestinal tract, and oral formulations for buccal delivery.

  • Diabetes
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Sanofi S.A.

It also offers assays for breast, colon, pancreatic, testicular, gastrointestinal, liver, ovarian, and prostate cancer; cardiac (CVDs); fertility/ pregnancy; infectious disease (next-generation blood screening and hematology); and metabolic (liver and kidney function).

  • Diabetes
  • World
  • Forecast
  • Bayer AG
  • Roche Group

GASTROINTESTINAL ADVERSE EFFECTS WERE MORE COMMON IN THE VICTOZA TREATMENT ARM COMPARED TO BYDUREON.

  • Diabetes
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

gastrointestinal, anti-infectious (antibacterial, antiviral), cardiovascular, anti-cancer, immunomodulant, reproductive, neurological, urological, dermatological and pediatric agents.

  • Diabetes
  • Asia
  • China
  • Demand
  • Zhejiang Expressway Co., Ltd.

GI = gastrointestinal.

  • Diabetes
  • World
  • Cepheid
  • Hologic, Inc.
  • Roche Group

Its Minimally Invasive Therapies Group segment provides gastrointestinal diagnostics, ablation, and interventional lung solutions; stapling, vessel sealing, and other surgical instruments; sutures; electrosurgery products; hernia mechanical devices; mesh implants; products for patient monit

  • Diabetes
  • World
  • Abbott
  • ARKRAY, Inc.
  • Bayer AG
  • Investigators Information

THE INCIDENCES OF THE PRE-SPECIFIED GASTROINTESTINAL AES OF ABDOMINAL PAIN, DIARRHEA, AND NAUSEA WERE LOW AND DID NOT DIFFER BETWEEN GROUPS.

  • Diabetes
  • Drug Discovery And Development
  • World
  • Merck & Co., Inc.
  • Novartis AG

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.
  • An overview of pancreas and diabetes

THESE AGENTS ARE ASSOCIATED WITH REDUCED RATES OF HYPOGLYCEMIA, MODERATE AND CONTINUOUS WEIGHT LOSS, AND GASTROINTESTINAL SIDE-EFFECTS SUCH AS NAUSEA AND VOMITING.

  • Diabetes
  • Forecast
  • Insulet Corporation
  • Medtronic, Inc.
  • Roche Group
  • RISK FACTORS & PREVENTION
  • INTRODUCTION

Gastrointestinal complications of diabetes.

  • Chronic Disease
  • Diabetes
  • Pathology
  • Europe
  • 3. INTRODUCTION

SGLT## REABSORBS GLUCOSE AND GALACTOSE IN THE GASTROINTESTINAL TRACT, WHEREAS SGLT## REABSORBS GLUCOSE IN THE KIDNEY.

  • Diabetes
  • Market Size
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • Sanofi S.A.

THE PHARMACEUTICAL SEGMENT INCLUDES PRODUCTS FOR ANTI-INFECTIVE, ANTIPSYCHOTIC, CARDIOVASCULAR, CONTRACEPTIVE, GASTROINTESTINAL, HAEMATOLOGY, IMMUNOLOGY, INFECTIOUS DISEASES, METABOLIC, NEUROLOGY, ONCOLOGY, PAIN MANAGEMENT AND VACCINES.

  • Diabetes
  • Europe
  • Forecast
  • Bayer AG
  • Medtronic, Inc.

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • PEPTIDE THERAPEUTICS IN METABOLIC DISORDERS: TECHNOLOGY PLATFORMS

THIS IS DONE TO DECREASE THE PROBABILITY OF GASTROINTESTINAL SYMPTOMS.

  • Diabetes
  • Endocrine Disease
  • United States
  • LipimetiX Development LLC
  • Novartis AG
  • Trial Results

GASTROINTESTINAL, AUTOIMMUNE DISEASE HISTORY OF MALIGNANCY, DRUG OR ALCOHOL ABUSE PARTICIPATION IN ANY PREVIOUS TRIAL ON ACE INHIBITOR TAKING OTHER INVESTIGATIONAL DRUGS WITHIN THE PAST ## DAYS KNOWN HISTORY OF SENSITIVITY / ALLERGY TO ACE INHIBITOR EXPECTED SURVIVAL LESS THAN ## YEARS

  • Diabetes
  • World
  • Anthera Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Novartis AG

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES; ##(##): ##-##.

  • Diabetes
  • Japan
  • Conatus Pharmaceuticals Inc.
  • Galectin Therapeutics Inc.
  • Gilead Sciences, Inc.